Ashland Inc. is a specialty materials company serving markets including pharmaceuticals, personal care, food and beverages, coatings, construction, energy, and electronics. It operates through four segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. Life Sciences contributes the highest revenue, offering functional additives for pharmaceutical and nutrition applications. Personal Care provides ingredients for skin, hair, oral care, and household products, while Specialty Additives supplies performance-enhancing additives for coatings and. Intermediates produce BDO and related derivatives used in polymers, electronics, agriculture, and pharmaceutical applications. The company generates sales across North America, Europe, Asia Pacific, Latin America, and regions.
Last trade$74.23
Day change-$1.34 (-1.77%)
Day range$73.91 – $75.80
Volume248,290
Market cap$3.46B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.46B
Price / earnings
62.92×
Price / book
1.85×
Price / sales
1.88×
EV / sales
2.39×
EV / EBITDA
26.47×
Profitability
Earnings per share
$1.20
Return on assets
1.2%
Return on equity
2.94%
Dividend yield
2.2%
Liquidity and leverage
Debt / equity
0.73×
Current ratio
3.05×
Quick ratio
1.89×
Cash ratio
1.04×
Cash flow
Price / cash flow
10.75×
Price / free cash flow
14.6×
Free cash flow
$237M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ASH, quarterly periods
Line item
Q3 FY2026 Jun 30, 2026
Q2 FY2026 Mar 31, 2026
Q1 FY2026 Dec 31, 2025
Q4 FY2025 Sep 30, 2025
Q3 FY2025 Jun 30, 2025
Q2 FY2025 Mar 31, 2025
Q1 FY2025 Dec 31, 2024
Q4 FY2024 Sep 30, 2024
Revenue
$497M
$482M
$386M
$477M
$463M
$479M
$405M
$522M
Cost of revenue
$327M
$335M
$281M
$318M
$331M
$332M
$294M
$348M
Gross profit
$170M
$147M
$105M
$159M
$132M
$147M
$111M
$174M
Selling, general and administrative
$99M
$79M
$86M
$76M
$106M
$85M
$78M
$101M
Research and development
$15M
$14M
$13M
$13M
$13M
$14M
$13M
$13M
Total operating expenses
$129M
$108M
$112M
$101M
$134M
$114M
$291M
$146M
Operating income
$41M
$39M
-$7M
$58M
-$2M
$33M
-$180M
$28M
Interest expense
$8M
$0
-$8M
$1M
$5M
$0
-$28M
$10M
Income before taxes
$56M
$20M
-$15M
$65M
-$704M
$39M
-$209M
$25M
Income taxes
$15M
$5M
-$1M
$32M
$15M
$9M
-$43M
$6M
Net income
$41M
$16M
-$12M
$32M
-$719M
$31M
-$165M
$16M
Net income attributable to common shareholders
$41M
$16M
-$12M
$10M
-$719M
$31M
-$165M
-$11M
EBITDA
$89M
$84M
$39M
-$46M
$74M
$93M
$54M
-$19M
Basic earnings per share
$0.89
$0.34
-$0.26
$0.22
-$15.70
$0.65
-$3.50
-$0.23
Diluted earnings per share
$0.89
$0.34
-$0.26
$0.22
-$15.70
$0.65
-$3.50
-$0.23
Recent news
Company coverage with links to the original publishers.
Ashland Inc. announced a quarterly cash dividend of $0.42 per share, payable on December 15, 2026, to shareholders of record as of December 1, 2026. The company has 45,833,893 shares outstanding as of October 31, 2026.
Ashland Inc. (ASH) reported fiscal Q4 adjusted EPS of $1.12, missing consensus estimates by 13.8%, though sales grew 4.2% to $498 million. Personal Care segment showed strong 8% growth while Life Sciences gained 4%. The company projects fiscal 2027 sales of $1.905-$1.975 billion (2-6% growth) and adjusted EBITDA of $405-$435 million, with improved free cash flow conversion and resilient demand expected in key segments.
Ashland reported quarterly earnings of $1.12 per share, missing consensus estimates of $1.30 and delivering a -13.85% earnings surprise. Revenues also fell short of expectations at $498 million. The company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revisions, though it has outperformed the S&P 500 by 26.5% year-to-date. Peer company Ingevity is expected to report results on November 4 with anticipated earnings of $1.56 per share, representing 19.1% year-over-year growth.
Ashland reported Q3 2026 revenue of $498 million, up 4.2% year-over-year and slightly missing the consensus estimate of $500.66 million. However, EPS of $1.12 fell short of the $1.30 consensus estimate by 13.85%. The company showed mixed segment performance, with Personal Care revenue exceeding expectations (+8% YoY) while Specialty Additives underperformed. Ashland carries a Zacks Rank #4 (Sell) rating.
Sensient Technologies reported Q3 2026 earnings of $1.13 per share, beating consensus estimates of $1.03, with revenues of $455.84 million also exceeding expectations. The company has outperformed the S&P 500 by 40% year-to-date. However, the stock received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, suggesting near-term performance in line with the market.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
Declared upcoming dividend$0.42 per share
Declared
Nov 11, 2026
Ex-dividend
Dec 1, 2026
Pay date
Dec 15, 2026
Ex-dividend
Amount / share
Pay date
Type
Sep 1, 2026
$0.42
Sep 15, 2026
recurring
Jun 1, 2026
$0.42
Jun 15, 2026
recurring
Feb 27, 2026
$0.415
Mar 15, 2026
recurring
Dec 1, 2025
$0.415
Dec 15, 2025
recurring
Aug 29, 2025
$0.415
Sep 15, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.